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Ke
ISSBACKGROUND Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high
risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase
subtilisin–kexin type 9 inhibition in such patients is undetermined.
OBJECTIVES This pre-speciﬁed analysis from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an
Acute Coronary Syndrome During Treatment With Alirocumab) determined whether polyvascular disease inﬂuenced risks
of MACEs and death and their modiﬁcation by alirocumab in patients with recent ACS and dyslipidemia despite intensive
statin therapy.
METHODS Patients were randomized to alirocumab or placebo 1 to 12 months after ACS. The primary MACEs endpoint
was the composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or
unstable angina requiring hospitalization. All-cause death was a secondary endpoint.
RESULTS Median follow-up was 2.8 years. Of 18,924 patients, 17,370 had monovascular (coronary) disease, 1,405 had
polyvascular disease in 2 beds (coronary and peripheral artery or cerebrovascular), and 149 had polyvascular disease in
3 beds (coronary, peripheral artery, cerebrovascular). With placebo, the incidence of MACEs by respective vascular cate-
gories was 10.0%, 22.2%, and 39.7%. With alirocumab, the corresponding absolute risk reduction was 1.4% (95% conﬁ-
dence interval [CI]: 0.6% to 2.3%), 1.9% (95% CI:2.4% to 6.2%), and 13.0% (95% CI:2.0% to 28.0%). With placebo,
the incidence of death by respective vascular categories was 3.5%, 10.0%, and 21.8%; the absolute risk reduction with
alirocumab was 0.4% (95% CI: 0.1% to 1.0%), 1.3% (95% CI: 1.8% to 4.3%), and 16.2% (95% CI: 5.5% to 26.8%).
CONCLUSIONS In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyvascular disease is
associated with high risks of MACEs and death. The large absolute reductions in those risks with alirocumab are a po-
tential beneﬁt for these patients. (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During
Treatment With Alirocumab [ODYSSEY OUTCOMES]: NCT01663402) (J Am Coll Cardiol 2019;74:1167–76)
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1168P atients with peripheral artery disease(PAD) or cerebrovascular disease(CeVD) have an elevated risk of ma-
jor adverse cardiovascular events (MACEs)
and death compared with patients without
these conditions, irrespective of a concur-
rent history of coronary artery disease
(CAD) (1–3). The risk of future MACEs and
death also remains high among patients
with an acute coronary syndrome (ACS),
despite application of evidence-based sec-
ondary prevention measures including sta-
tins and dual antiplatelet therapy (4).
When PAD or CeVD is concurrent with ACS,
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1169The advent of inhibitors of proprotein convertase
subtilisin–kexin type 9 (PCSK9) provided an op-
portunity to lower LDL-C to levels not previously
achievable with statins or ezetimibe. The FOURIER
(Further Cardiovascular Outcomes Research With
PCSK9 Inhibition in Subjects With Elevated Risk)
trial compared the PCSK9 inhibitor evolocumab
with placebo in patients with established, stable
atherosclerotic cardiovascular disease, including
CAD, PAD, or CeVD. Evolocumab reduced MACEs,
but not death. Beneﬁts were particularly pro-
nounced among patients with PAD at entry into the
trial (12).
The ODYSSEY OUTCOMES (Evaluation of Cardio-
vascular Outcomes After an Acute Coronary Syn-
drome During Treatment With Alirocumab) trial
showed that MACEs were reduced with the PCSK9
inhibitor alirocumab compared with placebo in 18,924
patients with recent ACS and elevated atherogenic
lipoproteins despite intensive statin therapy. In
addition, fewer deaths occurred among patients
treated with alirocumab. The aims of this pre-
speciﬁed analysis of the ODYSSEY OUTCOMES trial
were to determine whether the beneﬁts of alirocumab
on MACE and death were inﬂuenced by the presence
of polyvascular disease, deﬁned as concomitant PAD,
CeVD, or both, and thus to identify preferred candi-
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Details of the study design (13) and primary efﬁcacy
and safety results have been published (14). In brief,
ODYSSEY OUTCOMES was a multicenter, double-
blind, placebo-controlled trial in 18,924 patients at
least 40 years of age who provided written informed
consent and had been hospitalized with an ACS
(deﬁned as myocardial infarction or unstable angina)
1 to 12 months before randomization. Qualifying pa-
tients had a level of LDL-C of at least 70 mg/dl
(1.81 mmol/l), non–high-density lipoprotein choles-
terol at least 100 mg/dl (2.59 mmol/l), or apolipopro-
tein B at least 80 mg/dl, measured after a minimum of
2 weeks of stable treatment with atorvastatin 40 to
80 mg daily, rosuvastatin 20 to 40 mg daily, or the
maximum tolerated dose of either statin (including
no statin in case of documented intolerance). Patients
were randomly assigned in a 1:1 ratio stratiﬁed by
country to receive treatment with alirocumab 75 mg
subcutaneously every 2 weeks or matching placebo.
CATEGORIES OF POLYVASCULAR DISEASE. In this
analysis, 3 subgroups of patients with recent ACS
were deﬁned on the basis of the distribution of other
evident vascular disease: 1) monovascular disease
(CAD without known PAD or CeVD); 2) polyvascular
disease in 2 vascular beds (CAD and either PAD or
CeVD); and 3) polyvascular disease in 3 vascular bedsnts from Daiichi-Sankyo, Luitpold, Merck, Novartis,
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TABLE 1 Baseline Characteristics by History of PAD or CeVD Category
Monovascular Disease Disease in 2 Vascular Beds Disease in 3 Vascular Beds
CAD Without PAD
or CeVD
(n ¼ 17,370)
CAD and PAD
(n ¼ 610)
CAD and CeVD
(n ¼ 795)
CAD, PAD, and CeVD
(n ¼ 149) p Value
Age, yrs 58 (51, 65) 62 (56, 68) 62 (56, 69) 66 (60, 71) <0.0001
Age category <0.0001
<65 yrs 12,956 (74.6) 368 (60.3) 456 (57.4) 60 (40.3)
65 to <75 yrs 3,575 (20.6) 178 (29.2) 252 (31.7) 72 (48.3)
$75 yrs 839 (4.8) 64 (10.5) 87 (10.9) 17 (11.4)
Female 4,298 (24.7) 163 (26.7) 264 (33.2) 37 (24.8) <0.0001
Region <0.0001
Western Europe 3,852 (22.2) 152 (24.9) 142 (17.9) 29 (19.5)
Eastern Europe 4,993 (28.7) 189 (31.0) 215 (27.0) 40 (26.8)
North America 2,513 (14.5) 134 (22.0) 170 (21.4) 54 (36.2)
South America 2,413 (13.9) 64 (10.5) 101 (12.7) 10 (6.7)
Asia 2,170 (12.5) 22 (3.6) 92 (11.6) 9 (6.0)
Rest of world 1,429 (8.2) 49 (8.0) 75 (9.4) 7 (4.7)
Index event <0.0001
NSTEMI 8,300 (47.9) 342 (56.3) 439 (55.4) 94 (63.1)
STEMI 6,080 (35.1) 195 (31.1) 227 (28.6) 34 (22.8)
Unstable angina 2,963 (17.1) 71 (11.7) 127 (16.0) 21 (14.1)
Time from index event to
randomization, months
2.6 (1.7, 4.3) 3.0 (1.8, 5.4) 2.7 (1.7, 4.8) 3.0 (2.1, 3.9) 0.0003
Lipid-lowering therapy at randomization <0.0001
High-dose atorvastatin or rosuvastatin 15,486 (89.2) 525 (86.1) 679 (85.4) 121 (81.2)
Other LLT 1,734 (10.0) 75 (12.3) 102 (12.8) 24 (16.1)
No LLT 150 (0.9) 10 (1.6) 14 (1.8) 4 (2.7)
LDL-C, mg/dl 86 (73, 103) 91 (76, 108) 90 (75, 109) 95 (80, 115) <0.0001
LDL-C $100 mg/dl 5,060 (29.1) 218 (35.7) 290 (36.5) 61 (40.9) <0.0001
HDL-C, mg/dl 42 (36, 50) 42 (36, 50) 43 (36, 51) 43 (37, 51) NS
Non–HDL-C, mg/dl 114 (99, 136) 121 (105, 143) 120 (103, 144) 124 (108, 143) <0.0001
Triglycerides, mg/dl 128 (94, 181) 134 (99, 187) 136 (98, 190) 135 (94, 182) 0.002
Apolipoprotein B, mg/dl 79 (69, 93) 83 (72, 96) 83 (71, 96) 82 (75, 95) <0.0001
Lipoprotein(a), mg/dl 20.8 (6.6, 59.4) 25.5 (7.5, 68.1) 23.0 (7.1, 61.7) 29.4 (9.4, 74.5) 0.004
C-reactive protein, mg/dl 0.16 (0.08, 3.73) 0.26 (0.11, 0.55) 0.22 (0.10, 0.48) 0.21 (0.11, 0.49) <0.0001
Body mass index, kg/m2 27.9 (25.2, 31.1) 27.7 (24.9, 31.0) 28.1 (25.4, 31.5) 27.7 (24.5, 30.7) NS
Hemoglobin A1c, % 5.8 (5.5, 6.3) 6.0 (5.6, 6.7) 6.1 (5.7, 7.0) 6.0 (5.7, 6.7) <0.0001
eGFR, ml/min/1.73 m2 78.5 (68.1, 90.4) 74.1 (61.6, 86.7) 72.9 (59.5, 85.8) 67.0 (52.2, 84.4) <0.0001
eGFR <60 ml/min/1.73 m2 2,139 (12.3) 135 (22.1) 206 (25.9) 59 (39.6) <0.0001
Diabetes status <0.0001
Diabetes 4,805 (27.7) 225 (36.9) 349 (43.9) 65 (43.6)
Pre-diabetes 7,630 (43.9) 260 (42.6) 299 (37.6) 57 (38.3)
Normoglycemia 4,935 (28.4) 125 (20.5) 147 (18.5) 27 (18.1)
Smoking status <0.0001
Current 4,181 (24.1) 189 (31.0) 147 (18.5) 43 (28.9)
Former 7,095 (40.8) 302 (49.5) 335 (42.1) 79 (53.0)
Never 6,093 (35.1) 119 (19.5) 313 (39.4) 27 (18.1)
Medical history prior to index event
Hypertension 10,930 (62.9) 489 (80.2) 694 (87.3) 136 (91.3) <0.0001
Myocardial infarction 3,147 (18.1) 204 (33.4) 226 (28.4) 62 (41.6) <0.0001
Stroke 0 (0.0) 0 (0.0) 526 (66.2) 85 (57.0) <0.0001
Malignant disease 458 (2.6) 28 (4.6) 34 (4.3) 12 (8.1) <0.0001
COPD 613 (3.5) 64 (10.5) 46 (5.8) 23 (15.4) <0.0001
CABG 826 (4.8) 82 (13.4) 91 (11.4) 48 (32.2) <0.0001
PAD 0 (0.0) 610 (100.0) 0 (0.0) 149 (100.0) <0.0001
CeVD 0 (0.0) 0 (0.0) 795 (100.0) 149 (100.0) <0.0001
Continued on the next page
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TABLE 1 Continued
Monovascular Disease Disease in 2 Vascular Beds Disease in 3 Vascular Beds
CAD Without PAD
or CeVD
(n ¼ 17,370)
CAD and PAD
(n ¼ 610)
CAD and CeVD
(n ¼ 795)
CAD, PAD, and CeVD
(n ¼ 149) p Value
Revascularization for index event 12,596 (72.5) 436 (71.5) 540 (67.9) 105 (70.5) 0.04
Medications
Aspirin 16,647 (95.8) 564 (92.5) 737 (92.7) 138 (92.6) <0.0001
P2Y12 antagonist 15,223 (87.6) 525 (86.1) 664 (83.5) 129 (86.6) 0.005
ACE inhibitor/ARB 13,444 (77.4) 494 (81.0) 655 (82.4) 123 (82.6) 0.0008
Beta-blocker 14,687 (84.6) 507 (83.1) 672 (84.5) 124 (83.2) NS
Ezetimibe 473 (2.7) 38 (6.2) 30 (3.8) 13 (8.7) <0.0001
Treatment variables among
alirocumab-treated patients
8,683 302 406 71
% switched to placebo 691 (8.0) 12 (4.0) 25 (6.2) 2 (2.8) 0.01
Values are median (quartile 1, quartile 3), n (%), or n. The p values reﬂect the statistical comparison among the 4 vascular disease subgroups (CAD without PAD or CeVD; CAD
and PAD; CAD and CeVD; CAD PAD, and CeVD).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CeVD ¼ cerebrovascular
disease; COPD ¼ chronic obstructive pulmonary disease; eGFR ¼ estimated glomerular ﬁltration rate; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density
lipoprotein cholesterol; LLT ¼ lipid-lowering therapy; NS ¼ not signiﬁcant (p > 0.05); NSTEMI ¼ non–ST-segment elevation myocardial infarction; PAD ¼ peripheral artery
disease; STEMI ¼ ST-segment elevation myocardial infarction.
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1171(CAD with both PAD and CeVD). Two additional
sensitivity analyses were performed. The ﬁrst
considered 2 vascular disease categories: 1) mono-
vascular disease (CAD without known PAD or CeVD);
and 2) polyvascular disease (CAD with any combina-
tion of PAD or CeVD). The second analysis considered
4 subgroups of patients with ACS: 1) those with
monovascular disease, as deﬁned earlier; 2) all pa-
tients with PAD, with or without concurrent CeVD; 3)
all patients with CeVD, with or without concurrent
PAD; and 4) patients with disease in all 3 vascular
beds, as deﬁned earlier. PAD included arterial disease
of the extremities or abdominal aortic aneurysm.
CeVD was deﬁned as a history of carotid endarterec-
tomy, carotid stenting, prior stroke, or transient
ischemic attack.
ENDPOINTS. The primary MACE endpoint was a
composite of coronary heart disease death, nonfatal
myocardial infarction, fatal or nonfatal ischemic
stroke, or unstable angina requiring hospitalization.
All-cause death was a secondary endpoint.
STATISTICAL CONSIDERATIONS. Analyses of clin-
ical outcomes and LDL-C levels were performed
according to the intention-to-treat principle,
including all patients, events, and measurements
from randomization to the common study end date
(November 11, 2017). Hazard ratios and 95% conﬁ-
dence intervals (CIs) were estimated using a Cox
proportional hazards model, stratiﬁed by geographic
region; p values were determined using stratiﬁed
log-rank tests. Endpoint rates were based on
observed incidences. Alirocumab treatment effectheterogeneity by categories of polyvascular disease
was assessed by Cox models with interaction terms
for relative risk reduction and Gail-Simon tests for
absolute risk reduction (ARR). Analyses were per-
formed in SAS software version 9.4 (IBM Corp.,
Armonk, New York).
RESULTS
Of 18,924 randomized patients, 9,462 were assigned
to the alirocumab group and 9,462 to the placebo
group, with a median (quartile 1, quartile 3) follow-up
of 2.8 years (2.3, 3.4 years). At baseline, 17,370 pa-
tients had monovascular disease (91.8%), 1,405 pa-
tients had polyvascular disease in 2 vascular beds
(7.4%; 3.2% PAD and 4.2% CeVD), and 149 had poly-
vascular disease in 3 vascular beds (0.8%).
BASELINE CHARACTERISTICS. Table 1 summarizes
the baseline characteristics of patients with mono-
vascular (coronary) disease, polyvascular disease in 2
beds (split by PAD only and CeVD only), and poly-
vascular disease in 3 beds. Compared with patients
with monovascular disease, those with CAD and
PAD, CAD and CeVD, and polyvascular disease in 3
beds were older (median ages 58, 62, 62, and 66
years; p < 0.0001); patients with CAD and PAD or
CAD and CeVD were more likely to be female (26.7%
and 33.2%, respectively) than those with mono-
vascular disease (24.7%; p < 0.0001). Of all patients
with CeVD, 526 (66.2%) had a history of stroke. Pa-
tients with polyvascular disease in 3 beds had more
comorbidities, including a history of hypertension,
myocardial infarction, and coronary artery bypass
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Kaplan-Meier curves for primary major adverse cardiovascular event (MACE) endpoint in patients with arterial disease in, respectively,
1 (coronary artery disease [CAD] and no peripheral artery disease [PAD] or cerebrovascular disease [CeVD]), 2 (CAD and PAD or CeVD), or
3 (CAD and PAD and CeVD) vascular beds. ARR ¼ absolute risk reduction; CI ¼ conﬁdence interval.
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1172grafting, compared with patients with monovascular
disease (all p < 0.0001). Furthermore, patients with
polyvascular disease in 3 beds versus patients with
monovascular disease had a higher prevalence of
diabetes (43.6% vs. 27.7%; p < 0.0001) and were
more likely to be current or former smokers (81.9%
vs. 64.9%; p < 0.0001). More patients with poly-
vascular disease in 3 beds versus patients with
monovascular disease had an estimated glomerular
ﬁltration rate of <60 ml/min/1.73 m2 (39.6% vs.
12.3%) with median estimated glomerular ﬁltration
rates of 78.5, 74.1, 72.9, and 67.0 ml/min/1.73 m2 in
patients with monovascular disease, CAD and PAD,
CAD and CeVD, and polyvascular disease in 3 beds,
respectively (p < 0.0001).
LDL-C LOWERING. At baseline, median LDL-C
(quartile 1, quartile 3) was higher in patients with
polyvascular disease, with values of 86 mg/dl
(73, 103 mg/dl) in patients with monovasculardisease, 91 mg/dl (76, 108 mg/dl) in CAD and PAD,
90 mg/dl (75, 109 mg/dl) in CAD and CeVD, and
95 mg/dl (80, 115 mg/dl) in polyvascular disease in 3
beds (p < 0.0001). In the placebo group, LDL-C at
4 months was 87mg/dl (72, 106mg/dl) in patients with
monovascular disease, 90mg/dl (73, 108mg/dl) in only
PAD, 90 mg/dl (73, 115 mg/dl) in CeVD only, and
93 mg/dl (78, 118 mg/dl) in polyvascular disease in
3 beds. In patients treated with alirocumab, LDL-C at
4 months was 30 mg/dl (20, 47 mg/dl), 34 (23,
50 mg/dl), 34 mg/dl (21, 52 mg/dl), and 31 mg/dl (20,
42 mg/dl) in the same 4 vascular disease categories.
PRIMARY MACE ENDPOINT AND ALL-CAUSE
DEATH. Overall in the ODYSSEY OUTCOMES trial,
the incidence of MACE in the placebo and alirocumab
groups was 11.1% and 9.5%, respectively, with a cor-
responding ARR of 1.6% (95% CI: 0.7% to 2.4%;
p ¼ 0.0003) (14). The Central Illustration and Online
Figure 1 show that this overall efﬁcacy reﬂects a
TABLE 2 Primary MACE Endpoint and All-Cause Death by History of PAD or CeVD Category
Alirocumab Placebo HR* (95% CI)
HR Interaction
p Value* ARR (95% CI)
ARR Interaction
p Value*
Primary composite
Monovascular disease
(CAD without PAD or CeVD)
740/8,683 (8.5) 866/8,687 (10.0) 0.85 (0.77 to 0.93)
0.40
1.4 (0.6 to 2.3)
0.0006
Disease in 2 vascular beds
CAD and PAD 69/302 (22.8) 73/308 (23.7) 0.93 (0.67 to 1.30) 0.9 (5.9 to 7.6)
CAD and CeVD 75/406 (18.5) 82/389 (21.1) 0.87 (0.63 to 1.19) 2.6 (2.9 to 8.2)
Disease in 3 vascular beds
(CAD, PAD, and CeVD)
19/71 (26.8) 31/78 (39.7) 0.64 (0.35 to 1.12) 13.0 (2.0 to 28.0)
All patients 903/9,462 (9.5) 1,052/9,462 (11.1) 0.85 (0.78 to 0.93) 1.6 (0.7 to 2.4)
All-cause death
Monovascular disease
(CAD without PAD or CeVD)
268/8,683 (3.1) 305/8,687 (3.5) 0.88 (0.75 to 1.04)
0.06
0.4 (0.1 to 1.0)
0.002
Disease in 2 vascular beds
CAD and PAD 28/302 (9.3) 27/308 (8.8) 1.03 (0.60 to 1.75) 0.5 (5.1 to 4.0)
CAD and CeVD 34/406 (8.4) 43/389 (11.1) 0.68 (0.44 to 1.08) 2.7 (1.4 to 6.8)
Disease in 3 vascular beds
(CAD, PAD, and CeVD)
4/71 (5.6) 17/78 (21.8) 0.23 (0.08 to 0.68) 16.2 (5.5 to 26.8)
All patients 334/9,462 (3.5) 392/9,462 (4.1) 0.85 (0.77 to 0.98) 0.6 (0.1 to 1.2)
Values are n/N (%) unless otherwise indicated. *HRs reﬂect stratiﬁcation by geographic region in models with interaction between treatment and the 3 disease bed subgroups (monovascular
disease, disease in 2 beds, and disease in 3 beds).
ARR ¼ absolute risk reduction; CAD ¼ coronary artery disease; CI ¼ conﬁdence interval; HR ¼ hazard ratio; MACE ¼ major adverse cardiovascular event; other abbreviations as in Table 1.
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1173gradient of absolute risk and ARR according to the
number of diseased vascular beds. For patients in the
placebo group with 1, 2, or 3 diseased vascular beds,
the incidence of MACEs was 10.0%, 22.2%, and 39.7%,
respectively. The corresponding ARR with alirocumab
was 1.4% (95% CI: 0.6% to 2.3%), 1.9% (95% CI: 2.4%TABLE 3 Safety Endpoints
Monovascular Disease
CAD Without PAD or CeV
Alirocumab
(n ¼ 8,672)
Place
(n ¼ 8,
Any adverse event 6,532 (75.3) 6,619 (
Serious adverse event 1,905 (22.0) 2,012 (
Adverse event that led to death 143 (1.6) 175 (2
Adverse event that led to treatment
discontinuation
298 (3.4) 285 (
Local injection-site reaction 339 (3.9) 185 (
General allergic reaction 670 (7.7) 643 (
Diabetes worsening or diabetic complication
in patients with diabetes at baseline
444/2,369 (18.7) 521/2,427
New-onset diabetes among patients
without diabetes at baseline*
595/6,303 (9.4) 617/6,24
Neurocognitive disorder 120 (1.4) 143 (1
Hepatic disorder 450 (5.2) 493 (
Cataracts 99 (1.1) 117 (1
Hemorrhagic stroke, adjudicated
(fatal and nonfatal)
10 (0.1) 13 (0
Values are n (%) or n/N (%). *New-onset diabetes was deﬁned according to the presence
diabetes: an adverse event report, a new prescription for diabetes medication, a glycat
of $126 mg/dl (7.0 mmol/l) on 2 occasions (and a baseline level of <126 mg/dl).
Abbreviations as in Table 1.to 6.2%), and 13.0% (95% CI: 2.0% to 28.0%), with an
interaction p ¼ 0.0006.
For all-cause death in ODYSSEY OUTCOMES, the
overall incidence of death in the placebo and alir-
ocumab groupswas 4.1% and 3.5%, respectively,with a
corresponding ARR of 0.6% (95% CI: 0.2% to 1.2%) (14).Disease in 2 Vascular Beds
Disease in 3 Vascular
Beds
D CAD and PAD CAD and CeVD CAD, PAD, and CeVD
bo
668)
Alirocumab
(n ¼ 302)
Placebo
(n ¼ 308)
Alirocumab
(n ¼ 406)
Placebo
(n ¼ 389)
Alirocumab
(n ¼ 71)
Placebo
(n ¼ 78)
76.4) 250 (82.8) 262 (85.1) 321 (79.1) 328 (84.3) 62 (87.3) 73 (93.6)
23.2) 124 (41.1) 142 (46.1) 136 (33.5) 151 (38.8) 37 (52.1) 45 (57.7)
.0) 15 (5.0) 15 (4.9) 22 (5.4) 24 (6.2) 1 (1.4) 8 (10.3)
3.3) 21 (7.0) 15 (4.9) 19 (4.7) 18 (4.6) 5 (7.0) 6 (7.7)
2.1) 8 (2.6) 4 (1.3) 9 (2.2) 11 (2.8) 4 (5.6) 3 (3.8)
7.4) 31 (10.3) 38 (12.3) 41 (10.1) 45 (11.6) 6 (8.5) 10 (12.8)
(21.5) 23/99 (2.3) 28/126 (22.2) 29/188 (15.4) 32/161 (19.9) 10/32 (31.3) 2/33 (6.1)
1 (9.9) 26/203 (12.8) 22/182 (12.1) 24/218 (11.0) 32/228 (14.0) 3/39 (7.7) 5/45 (11.1)
.6) 6 (2.0) 10 (3.2) 9 (2.2) 10 (2.6) 8 (11.3) 4 (5.1)
5.7) 19 (6.3) 18 (5.8) 24 (5.9) 21 (5.4) 7 (9.9) 2 (2.6)
.3) 8 (2.6) 9 (2.9) 10 (2.5) 5 (1.3) 3 (4.2) 3 (3.8)
.1) 1 (0.3) 1 (0.3) 2 (0.5) 3 (0.8) 0 (0.0) 0 (0.0)
of 1 or more of the following, with conﬁrmation of the diagnosis by blinded external review by experts in the ﬁeld of
ed hemoglobin level of $6.5% on 2 occasions (and a baseline level of <6.5%), or a fasting serum glucose level
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1174Similar to MACEs, there was a gradient of absolute
risk and ARR with alirocumab. In the placebo group,
the incidence of death in patients with 1, 2, or 3
diseased vascular beds was 3.5%, 10.0%, and 21.8%,
respectively. With alirocumab, the corresponding
ARR was 0.4% (95% CI: 0.1% to 1.0%), 1.3%
(95% CI: 1.8% to 4.3%), and 16.2% (95% CI: 5.5% to
26.8%), with an interaction p ¼ 0.002.
Details of the primary MACE endpoint and all-
cause death are shown in Table 2, including the to-
tal number of events with corresponding hazard ratio
and ARR of alirocumab versus placebo for primary
endpoint and all-cause death for patients with mon-
ovascular disease, polyvascular disease in 2 or 3 beds,
polyvascular disease in 2 beds (split by PAD or CeVD),
and polyvascular disease in 3 beds. Online Tables 1
and 2 show these details for both sensitivity ana-
lyses (monovascular vs. polyvascular and the 4
overlapping vascular groups on the basis of PAD or
CeVD).
SAFETY OUTCOMES. Overall, there were no differ-
ences in the incidence of adverse events or laboratory
abnormalities between alirocumab and placebo
groups, with the exception of local injection-site re-
actions, which occurred more often in the alirocumab
group (14). Table 3 shows all safety endpoints for
alirocumab versus placebo for patients with mono-
vascular disease, polyvascular disease in 2 beds
(categorized as PAD or CeVD), and polyvascular dis-
ease in 3 beds. No major differences were observed
among the groups.
DISCUSSION
In patients with recent ACS and dyslipidemia despite
intensive statin therapy and high rates of guideline-
directed medical therapy, polyvascular disease is
associated with high risks of MACEs and death. The
large absolute reductions in both MACEs and death
with alirocumab therapy are a potential beneﬁt for
this group of patients.
This analysis of ODYSSEY OUTCOMES deﬁnes
easily identiﬁable subsets of patients with ACS with
high absolute risk and marked absolute beneﬁt of
PCSK9 inhibition with alirocumab. Identiﬁcation of
patient subsets likely to derive large absolute beneﬁt
is important (15,16).
Increasing risks of MACEs and death in patients
with an increasing number of affected vascular beds
have been described previously in large cohorts such
as the REACH (Reduction of Atherothrombosis for
Continued Health), CRUSADE (Can Rapid RiskStratiﬁcation of Unstable Angina Patients Suppress
Adverse Outcomes with Early Implementation of the
American College of Cardiology/American Heart As-
sociation Guidelines), and the American Heart Asso-
ciation Get With the Guidelines registries (2,5,17), but
they remain a therapeutic challenge. It is likely that
the elevated cardiovascular risk associated with
polyvascular disease is the result in part of clustering
of risk factors known to affect prognosis, including
older age and more frequent history of hypertension,
diabetes, prior myocardial infarction, coronary artery
bypass surgery, and chronic kidney disease, as was
observed in the present analysis. Dyslipidemia,
including higher levels of LDL-C and lipoprotein(a),
was also more pronounced in patients with poly-
vascular disease than in patients with monovascular
(coronary) disease (Table 1). Studies have shown that
high-intensity compared with low- to moderate-
intensity statin therapy reduces MACEs and death
in patients with polyvascular disease, including trials
with ACS, but also PAD and CeVD (7,18,19). Our
ﬁndings reinforce and extend this concept with
reduction of LDL-C to less than levels achievable with
statins by using alirocumab. Although alirocumab
produced a similar degree of LDL-C lowering in each
vascular category, a particularly pronounced absolute
reduction of MACEs and death was observed in pa-
tients with ACS and concurrent disease in other
vascular beds. Similar conclusions regarding MACEs
were drawn from an analysis of the FOURIER trial,
using the PCSK9 inhibitor evolocumab added to
statin in patients with stable, established athero-
sclerotic cardiovascular disease (12). In that analysis,
evolocumab reduced the risk of cardiovascular-
related events in patients with PAD. Of note,
because of trial selection criteria, patients with PAD
comprised 13.2% of the FOURIER cohort, compared
with 3.2% in ODYSSEY OUTCOMES (12). However,
some patients in FOURIER with PAD or CeVD had
monovascular disease in those territories.
Conversely, because qualiﬁcation for ODYSSEY
OUTCOMES required ACS, all patients with PAD or
CeVD had disease in at least 2 vascular beds.
STUDY LIMITATIONS. A substantial fraction of the
patients categorized as having monovascular (coro-
nary) disease may have had undetected PAD or CeVD,
given that they were not systematically evaluated for
those conditions at baseline. However, the classiﬁ-
cation used in the present analysis is representative
of daily clinical practice and decision making because
patients with ACS are not routinely screened for
polyvascular disease (20).
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Patients with polyvascular disease and ACS gain
considerable absolute beneﬁt from PCSK9 inhibition with
alirocumab.
TRANSLATIONAL OUTLOOK: Further studies are needed to
identify other subgroups of patients with atherosclerosis who
stand to gain substantial beneﬁt from PCSK9 inhibition.
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1175CONCLUSIONS
The present ﬁndings indicate that patients with
polyvascular disease comprise an easily identiﬁable
subgroup of patients with recent ACS with a high
absolute risk of MACEs and death. The large absolute
beneﬁt of PCSK9 inhibition with alirocumab, when
added to high-intensity statin therapy, is a potential
beneﬁt for this group of patients. However, further
studies are needed to guide the selection of patients
with ACS for treatment with a PCSK9 inhibitor in the
context of other established and evolving therapies in
atherosclerosis, so that efﬁcacy and efﬁciency are
optimized (21–23).
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